文献速递妇科

卵巢癌一线PARP抑制剂维持治疗:妇科肿瘤学会实践声明

Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
PubMed 文献 · Gynecol Oncol · 2020-08-07

PARP抑制剂在卵巢癌治疗中显示活性,四项随机3期试验确立了一线维持治疗的重要作用。BRCAm患者获益最大,HRD队列也有PFS改善但程度较低,HR proficient患者获益更有限。总生存数据尚不成熟。

要点

  • 四项随机3期试验确立PARP抑制剂一线维持治疗在卵巢癌中的重要地位。
  • BRCAm患者获益最大,HRD队列PFS改善但程度较低,HR proficient患者获益更有限。
  • 疲乏、血液学和胃肠道毒性是PARP抑制剂治疗最常见的不良事件。

核心结论

  • 四项随机3期试验已确立PARP抑制剂在卵巢癌一线维持治疗中的重要角色。
  • PARP抑制剂在BRCAm患者中获益最大,HRD队列PFS也有改善但程度较低。
  • HR proficient患者中PARP抑制剂治疗的总体影响较其他亚组更有限。
  • 四项试验的总生存数据目前尚不成熟。

研究设计与样本

  • 妇科肿瘤学会发布的实践声明。
  • 基于四项随机3期试验:SOLO-1、PRIMA、VELIA和PAOLA-1。
  • SOLO-1仅纳入BRCAm患者,PRIMA、VELIA和PAOLA-1纳入更广泛的患者人群。

主要发现

  • PARP抑制剂在BRCAm(胚系或肿瘤)患者中获益一致最大。
  • PARP抑制剂在HRD队列中改善PFS,但程度低于BRCAm患者。
  • HR proficient患者约占卵巢癌的50%,PARP抑制剂治疗的总体影响较其他亚组更有限。
  • 四项试验的总生存数据目前尚不成熟。
  • 疲乏、血液学和胃肠道毒性是PARP抑制剂治疗最常见的不良事件。

临床怎么用

  • FDA近期批准PARP抑制剂用于维持治疗,使临床医生能够将其纳入卵巢癌一线治疗武器库。

局限性

  • 四项试验的总生存数据目前尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PARP inhibitors (PARPi) have shown have activity in the treatment of ovarian cancer. Previous studies documented activity in patients with germline (gBRCA) and tumor (tBRCA) BRCA mutations (BRCAm) for treatment in lieu of chemotherapy as well as in recurrent ovarian cancer as maintenance therapy. The recent data from four randomized phase 3 trials have established an important role for frontline PARPi maintenance therapy in ovarian cancer. While SOLO-1 only included BRCAm patients, PRIMA, VELIA, and PAOLA-1 enrolled broader patient populations. The magnitude of benefit of PARPi in these studies was consistently greatest in the BRCAm patients (germline or tumor). PARPi treatment also improved PFS in the HRD cohort but to a lesser degree than in patients with BRCAm. In secondary analyses, the overall impact of PARPi treatment in HR proficient patients, which comprise about 50% of ovarian cancers, was more limited than in the other subgroups. Data for overall survival, also a secondary endpoint, is currently immature for these four trials. Fatigue, hematologic, and GI toxicities are the most commonly noted adverse events with PARPi therapy. The recent FDA approvals of PARPi in the maintenance setting will enable clinicians to incorporate these into frontline armamentarium of ovarian cancer treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Pothuri B, O'Cearbhaill R, Eskander R, et al. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. Gynecol Oncol. 2020. PMID: 32778410. doi:10.1016/j.ygyno.2020.07.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。